

Table 3: Estimated effects of HIP programme on primary and secondary outcomes at 53 weeks (Intention to Treat Analysis).

Measure	HIP Mean (sd)	TAU Mean (sd)	Effect ^a (95% CI) (adjusted for baseline) P =	Intra class correlation	Effect ^a (95% CI) (+adjusted for covariates) P=	Intra class correlation
SF36v2						
n patients	68	60	-	-	n =64,51	
k nurses	25	24			k=25,21	
SF36v2 PCS	Baseline ^b 53 Weeks	43.36(10.97) 44.64(12.47)	44.07(10.82) 43.80(11.30)	1.50 (-1.50, 4.50) P = 0.327	0.054 P=0.511	1.01(-2.0,4.0) P=0.511
SF36v2 MCS	Baseline ^b 53 Weeks	40.26(13.08) 40.81(13.58)	37.89(13.94) 38.18(14.94)	1.38(-3.07,5.82) P=0.543	0.028 p=0.561	1.26(-3.0,5.5) p=0.561
EQ5D VAS						
n patients	63	61			n=58,51	
k nurses	25	24			k = 25,21	
EQ5D VAS	Baseline ^b 53 Weeks	60.08(20.18) 55.57(24.61)	60.25(19.36) 58.11(20.35)	-2.30(-10.70,6.10) P=0.592	0.271 ^c P=0.263	-5.15 (-14.2,3.9) P=0.263
EQ5D						
n patients	66	57			n=61,51	
k nurses	24	24			K=24,21	
EQ5D	Baseline ^b 53 Weeks	0.632(0.306) 0.597(0.338)	0.607(0.330) 0.590(0.326)	-0.01(-0.11,0.09) P=0.870	0.030 p=0.478	-0.036(-0.134,0.063) p=0.478

a = Effect of HIP versus Treatment as usual

b = Baseline mean is of those with follow up data

c = 95% CI for the ICC (0.05304,0.4639) Note: *estimated* ICCs can be negative.

